Amy Simon
Net worth: 3 M $ as of 31/05/2026
Net worth: 3 M $ as of 31/05/2026
Amy Simon is Chief Medical Officer for Beam Therapeutics, Inc. In the past Dr. Simon held the position of Vice President-Clinical Development at Alnylam Pharmaceuticals, Inc. Dr. Simon received an undergraduate degree from Harvard University and a doctorate from Tufts University School of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/04/2026 | 1,02,735 ( 0.1% ) | 3 M $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| BEAM THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 15/03/2021 |
| Companies | Position | End |
|---|---|---|
Tufts University
Tufts University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Graduate School of Biomedical Sciences | Corporate Officer/Principal | - |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Tufts University
Tufts University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tufts University School of Medicine
Tufts University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Beam Therapeutics, Inc.
Beam Therapeutics, Inc. BiotechnologyHealth Technology Operate as a biotechnology company that develops precision genetic medicines, gene editing and delivery technologies | Health Technology |
Graduate School of Biomedical Sciences |
Select your edition
All financial news and data tailored to specific country editions